Y-mabs receives priority review status for cancer drug in China
A potential launch of Y-mabs's drug Danyelza is one step closer after being granted priority review status, ensuring a faster assessment by the Chinese authorities.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
In a collaboration with the partner Schiclone Pharmaceuticals, biopharmaceutical company Y-mabs has been granted priority review by China's National Medical Products Administration (NMPA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA requires more data from Y-mabs
For subscribers
.jpg&w=384&q=75)
